V. NIOSH Recommendations for Personal Respiratory Protection
44
- – The specific risks, non-medical consequences of acquiring, and medical consequences of acquiring tuberculosis infection (e.g., risk of developing clinical tuberculosis).
- – The efficacy, benefits, and specific risks of chemoprophylaxis with isoniazid indicated for those infected with tuberculosis (e.g., illness due to INH-induced hepatitis and possible death from hepatitis).
- – The specific risks and medical consequences of developing clinically active tuberculosis ( e.g., risk of death due to tuberculosis in treated and untreated infected persons; illness due to active tuberculosis; risks of transmission to coworkers, family members, patients or clients, and the general public).
- – The nature of transmission and the relative risk of transmission (i.e., infectiousness) due to the aerosolization of droplet nuclei from individuals with differing generation rates of infectious tuberculosis particles (i.e., transmitters) at varying locations and undergoing varying procedures in health-care facilities.
- – Some of the inherent practical limitations of personal respiratory protection programs, admission screening plans, employee tuberculosis skin-test surveillance programs, and infection-control programs that increase the hazard to health-care-workers due to airborne transmission of tuberculosis in their workplace.
- – Information about the risk for life-threatening clinical tuberculosis in persons with immunocompromising conditions.
- An explanation of why engineering controls are not being applied or are not adequate, and of what effort is being made to reduce or eliminate the need for personal respiratory protection.
